ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aclaris Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$3.48+0.20 (+6.10%)

Close on Oct 19, 2026

Market cap: $496.72M
P/E (TTM): –
Dividend yield: –

Aclaris Therapeutics, Inc. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Cash & Equivalents	20	25	40	45	27	22	36	57	20	30	9.85	11	9.59	19
Short-Term Investments	71	89	79	172	164	32	39	111	174	107	75	5.37	–	–
Cash & Short-Term Investments	151	204	182	230	226	54	75	168	209	174	92	16	9.59	19
Receivables	–	0.32	0.30	0.48	0.62	0.77	0.70	0.56	0.48	–	–	–	–	–
Inventory	–	–	–	–	–	–	0	0.79	–	–	–	–	–	–
Prepaid Expenses & Other	–	12	9.45	13	13	2.59	3.12	4.80	5.88	1.33	1.66	0.20	–	–
Total Current Assets	96	126	129	232	205	57	84	179	200	139	87	16	–	–
Property, Plant & Equipment	0.76	1.01	1.62	1.10	1.34	1.65	2.47	2.29	2.16	0.48	0.36	0.52	–	–
Gross Property, Plant & Equipment	–	5.81	5.78	5.13	4.73	4.28	4.54	3.61	2.64	0.61	0.40	0.54	–	–
Accumulated Depreciation	–	-4.81	-4.16	-4.04	-3.39	-2.62	-2.07	-1.32	-0.48	-0.13	-0.04	-0.03	–	–
Long-Term Investments	61	90	63	12	34	–	–	–	15	37	7.17	0.52	–	–
Goodwill	–	–	–	–	–	–	–	19	19	–	–	–	–	–
Intangible Assets	–	–	0.27	6.97	7.05	7.12	7.20	7.27	7.35	–	–	–	–	–
Other Long-Term Assets	2.77	3.07	4.16	2.73	3.55	4.51	4.83	0.33	0.28	0.14	0.02	0.01	–	–
Total Assets	160	220	197	255	251	71	98	276	244	176	94	17	–	–
Accounts Payable	13	4.69	8.88	10	9.99	5.25	9.92	12	7.82	2.85	0.81	1.26	–	–
Accrued Expenses	8.79	20	19	8.70	10	5.91	7.72	8.09	4.94	3.38	0.75	0.19	–	–
Current Portion of Leases	0.55	0.48	0.43	0.68	0.69	0.60	0.53	–	–	–	–	–	–	–
Deferred Revenue (Current)	3.94	3.89	–	–	–	–	–	–	–	–	–	–	–	–
Other Current Liabilities	2.75	2.68	2.63	–	0.69	0.60	0.64	0.14	–	–	–	–	–	–
Total Current Liabilities	29	32	31	22	23	15	22	27	13	6.22	1.56	1.45	–	–
Long-Term Leases	1.57	2.12	3.07	1.57	2.15	2.89	3.55	–	–	–	–	–	–	–
Operating Lease Liabilities	2.12	2.60	3.50	2.25	2.84	3.50	4.07	–	–	–	–	–	–	–
Deferred Tax Liabilities	–	–	–	0.37	0.37	0.37	0.55	0.55	0.55	–	–	–	–	–
Other Long-Term Liabilities	1.57	4.44	3.07	1.57	2.17	3.18	3.74	0.48	0.56	0.37	–	–	–	–
Total Liabilities	57	65	40	57	54	33	28	60	18	6.60	1.56	1.46	–	–
Common Stock	0.00	0.00	0.00	0.00	0.00	–	–	–	–	–	–	–	–	–
Additional Paid-In Capital	1,070	1,058	928	881	793	542	524	507	385	261	136	–	–	–
Retained Earnings	-968	-903	-771	-682	-595	-505	-454	-292	-159	-91	-43	-21	–	–
Comprehensive Income & Other	0.61	0.10	-0.11	-0.90	-0.22	-0.09	-0.07	-0.07	-0.25	-0.27	-0.15	-0.01	–	–
Shareholders' Equity	103	156	157	198	197	38	70	215	225	169	93	-21	-9.16	-2.19
Total Equity	103	156	157	198	197	38	70	215	225	169	93	-21	-9.16	-2.19
Total Liabilities & Equity	160	220	197	255	251	71	98	276	244	176	94	17	–	–
Shares Outstanding(shares)	120	108	71	67	61	45	41	41	31	26	20	2.73	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 79.5%
Operating margin: -1050.2%
Net margin: -921.5%
Return on equity, FY2025: -50.2%

Financial strength

Current ratio: 3.46
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 67.9%

Valuation

P/E ratio: –
Price to sales: 60.44
Price to book: 3.99
Dividend yield: –